Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Medizinska AkadfiledCriticalMedizinska Akad
Priority to BG9241290ApriorityCriticalpatent/BG51003A1/en
Publication of BG51003A1publicationCriticalpatent/BG51003A1/en
The vaccine is used for influenza prophylactics. The method is used to dissolve and extract electrophoretically pure viral glycoproteins of completely retained biological activity and inducing a high level of serum antibodies, as well as to form liposomes with a configuration that imitates the individual viral particles of the viral antigens in size and arrangement on the surface of the lipid bilayers. The solubilization of the purified influenza viruses is carried out with 5 per cent solution of detergent at a temperature of 20-22 degrees C for 30 to 35 minutes and a pH of 7.2. The formation of liposomes is done with endogenous viral lipids.
BG9241290A1990-07-101990-07-10Method for preparing of subunit liposome grippe vaccine
BG51003A1
(en)
Vaccine composition, method for treatment of mammals, diseased or receptive to the infection, method for treatment of mammals with cancer, method for production of vaccine composition, composition of adjuvants
Influenza virus‐specific T cell‐mediated cytotoxicity: integration of the virus antigen into the target cell membrane is essential for target cell formation
Alteration of the membrane lipid composition and infectivity of vesicular stomatitis virus by growth in a Chinese hamster ovary cell sterol mutant and in lipid-supplemented baby hamster kidney clone 21 cells.